TCT-599 Final procedural, 30-day and 6-month angiographic, clinical and OCT outcomes from the DIRECT II Trial using the Svelte Integrated Delivery System with Enzymatic Bioabsorbable Sirolimus Coating

Authors :: Pieter R. Stella
Victor Legrand
Jan Horák
Pieter C. Smits
Nicolas M. Van Mieghem
Jean Fajadet
Ahmed A. Khattab
Ton Slagboom
Stefan Verheye
Mathias Vrolix
Jacques Berland
Joachim Schofer
Didier Carrié
Source :: Journal of the American College of Cardiology. 64:B175
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.
Abstract: The Svelte (New Providence, NJ) sirolimus-eluting coronary stent utilizing a bioresorbable amino acid-based (PEA) drug carrier is mounted on a novel Integrated Delivery System (IDS) consisting of a low-compliant balloon with balloon control bands (BCBs) affixed to a 0.014 integrated wire with

Subjects :: medicine.medical_specialty
business.industry
medicine.medical_treatment
engineering.material
Balloon
Surgery
stomatognathic diseases
Coating
Sirolimus
Coronary stent
engineering
medicine
Delivery system
Cardiology and Cardiovascular Medicine
Drug carrier
business
medicine.drug

Full Text Access

Tools